CMPS stock will retrace at least 5% from its 2026-05-31 closing price within 10 trading days, absent a confirmatory catalyst (FDA meeting date announcement or partnership deal).

If Compass Pathways (a psilocybin biotech company) stock jumps up by early summer 2026 without real news like an FDA meeting announcement or a business deal, it will likely fall back down 5% or more within ten trading days. This matters because small biotech stocks move on hype, and when the hype fades, sellers take profits and the stock falls back.

Single-session ~10% moves in small-cap psychedelic biotech without hard catalysts have historically reverted: institutional holders use spikes to trim, retail momentum fades within 1-2 weeks. Falsifiable with a specific price threshold and deadline (resolve date: 2026-06-16). Condition clause makes it appropriately specific.